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Abstract
Background: BAY 1862864 is an a-particle emitting thorium-227-labeled CD22-targeting antibody. This first-
in-human dose-escalation phase I study evaluated BAY 1862864 in patients with CD22-positive relapsed/re-
fractory B cell non-Hodgkin lymphoma (R/R-NHL).
Materials and Methods: BAY 1862864 intravenous injections were administered at the starting thorium-227
radioactivity dose of 1.5 MBq (2 or 10 mg antibody), and the radioactivity dose escalated in *1.5 MBq
increments (10 mg antibody) until the maximum tolerated dose (MTD) was reported. The primary objective was
to determine the safety, tolerability, and MTD.
Results: Twenty-one patients received BAY 1862864. Two dose-limiting toxicities (grade 3 febrile neutropenia and
grade 4 thrombocytopenia) were reported in one patient in the 4.6 MBq (10 mg antibody) cohort. The MTD was not
reached. Ten (48%) patients reported grade ‡3 treatment-emergent adverse events, with the most common being
neutropenia, thrombocytopenia, and leukopenia, each occurring in 3 (14%) patients. Pharmacokinetics demon-
strated the dose proportionality and stability of BAY 1862864 in the blood. The objective response rate (ORR) was
25% (5/21 patients) according to the LUGANO 2014 criteria, including 1 complete and 4 partial responses. The
ORR was 11% (1/9) and 30% (3/10) in patients with relapsed high- and low-grade lymphomas, respectively.
Conclusions: BAY 1862864 was safe and tolerated in patients with R/R-NHL.
The Clinical Trial Registration numbers: NCT02581878 and EudraCT 2014-004140-36.
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Despite recent advances in cancer therapy, an urgent needfor new therapies for patients with relapsed or refractory
B cell non-Hodgkin lymphoma (R/R-NHL) remains. Prior
studies established the sensitivity of patients with R/R-NHL
to antigen-specific radionuclide-labeled antibodies and the
sensitivity of those with early-stage follicular lymphoma
(FL) to radiotherapy, which provided a rationale for the de-
velopment of targeted alpha therapy (TAT) for the treatment
of patients with NHL.1–4
TAT is a highly potent and selective anticancer treatment
that delivers high-energy a radiation to tumor cells and the
tumor microenvironment, leading to robust antitumor effects,
while minimizing damage to the surrounding normal tissue.5
a-particles have a high linear energy transfer, ranging from 50
to 230 keV/lm, which induces DNA double-strand breaks
leading to cell cycle arrest and subsequent cell death.5
Thorium-227 is an a-particle-emitting radionuclide with a
half-life of 18.7 d, which decays through an a-particle
emission to its first daughter radionuclide radium-223.6 The
physical half-life of thorium-227 is longer compared with
other clinically used a-particle-emitting radionuclides7 and
is compatible with the biological half-life of an antibody in
human plasma.
Thorium-227 can be efficiently complexed with the 3,2-
hydroxypyridinone (3,2-HOPO) chelator conjugated to an-
tibodies or other targeting moieties.8 The longer physical
half-life of thorium-227, and low radiolysis and degradation
rate of antibodies permit a pharmaceutical shelf life of 48 h
for the thorium-227-labeled antibodies.7
CD22 belongs to the B cell-specific immunoglobulin su-
perfamily and is expressed on the vast majority of R/R-NHL,
but is absent on the surface of stem cells, B cell progenitors,
and plasma cells.9,10 CD22 functions as a negative regulator
of B cell antigen receptor signaling.11 The validity of the
CD22-targeting approach has been shown in phase III studies
of the recombinant anti-CD22 immunotoxin, moxetumomab
pasudotox, in patients with CD22-positive hairy cell leukemia
and the yttrium-90-labeled epratuzumab (anti-CD22 anti-
body) tetraxetan in patients with NHL.12–14
The thorium-227-epratuzumab conjugate (BAY 1862864)
is composed of an anti-CD22 humanized monoclonal anti-
body (epratuzumab; Immunomedics, Inc., NJ) conjugated to
the 3,2-HOPO chelator at a chelator-antibody ratio of 0.8
and then labeled with thorium-227 at a nearly 100% yield.
BAY 1862864 has demonstrated a cytotoxic effect at na-
nomolar concentrations when tested on CD22-positive can-
cer cell lines. In preclinical animal models, BAY 1862864
prolonged the overall survival of BAY 1862864-treated
animals versus those who had received a control treatment
and was well tolerated.6
In this study, the authors report the safety, tolerability,
pharmacokinetic data, and efficacy for the dose-escalation
part of the first-in-human phase I study of BAY 1862864 in
patients with R/R-NHL.
Materials and Methods
Study design and patients
This was an open-label, phase I study of BAY 1862864 in
patients with CD22-positive R/R-NHL conducted in four
centers (one in Sweden and three in the UK). The study was
divided into a dose-escalation part, with a modified 3 + 3 de-
sign to determine the maximum tolerated dose (MTD), and an
expansion part. Four treatment cycles, each lasting for 42 d,
were planned, with additional injections allowed on the basis
of a case-by-case benefit–risk assessment. Eligible patients
were ‡18 years of age, had failed ‡1 prior chemotherapy or
immunotherapy-based regimen, had relapsed or were refrac-
tory to the last treatment regimen, were ineligible for or failed
high-dose therapy and autologous stem cell transplantation
(HDT-ASCT), and had measurable disease. Patients were
excluded if they had CD22-positive NHL with predominantly
clinical leukemic presentation. Full inclusion and exclusion
criteria are detailed in the Supplementary Data.
All patients provided written informed consent. The study
was conducted in accordance with the Declaration of Hel-
sinki, the International Conference on Harmonisation Good
Clinical Practice guidelines, and applicable local laws and
regulations. The protocol was reviewed and approved by the
independent ethics committees at all participating sites. The
study is registered in ClinicalTrials.gov (NCT02581878)
and European Union Drug Regulating Authorities Clinical
Trials Database (2014-004140-36).
Procedures and assessments
Validation of BAY 1862864 purity, identity, and stability
are described in the Supplementary Data.
BAY 1862864 was administered intravenously as a slow
bolus injection on day 1 of each 42-d treatment cycle. Pa-
tients were randomized 1:1 to receive either 2 or 10 mg of
epratuzumab-chelator conjugate at a starting radioactivity
dose of 1.5 MBq, based on nonclinical toxicology data.15
The antibody dose was set to 10 mg for all the subsequent
cohorts (the justification is given in the the Supplementary
Data). The thorium-227 radioactivity dose was escalated in
increments of *1.5 MBq, until the MTD was reported or a
biologically active dose was determined.
The National Cancer Institute’s Common Terminology
Criteria for Adverse Events version 4.03 were used to grade
toxicities and adverse events (AEs). The MTD was defined
as the lower preceding dose level to the toxic dose. At the
MTD, no more than one patient had to have experienced a
dose-limiting toxicity (DLT) (defined in the Supplementary
Data) out of six evaluable patients during the first 6 weeks of
treatment (cycle 1). The evaluation of the QT/QTc interval
was performed using the central triplicate 12-lead electro-
cardiography.
Pharmacokinetic evaluations and whole body measure-
ments for thorium-227 and radium-223 were performed as
described in the Supplementary Data.
Assessments of lymphoma lesions were carried out ac-
cording to the 2014 Lugano classification criteria16 using
computed tomography (CT) and positron emission tomog-
raphy (PET)-CT at screening, at the end of each cycle and at
the end of study visit (12 weeks after the last injection).
Study objectives
The primary objective was to determine the safety, tol-
erability, and MTD of BAY 1862864, as assessed by the
number of patients reporting DLTs during a period of up to
12 weeks after the first treatment.17 The exploratory
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objectives included the evaluation of biodistribution of BAY
1862864,18 pharmacokinetics, pharmacodynamics, immu-
nogenicity, biomarkers, and tumor response to the treatment
with BAY 1862864.
Statistical analyses
The choice of the number of patients per cohort was
based on the standard phase I design for toxicity assessment.
All patients who had received at least one dose of
BAY 1862864 were included in the safety analysis set (full
analysis set). The incidence of treatment-emergent AEs
(TEAEs) and drug-related TEAEs was determined as de-
scribed in the Supplementary Data.
All patients evaluable for pharmacokinetics and phar-
macodynamics, without major protocol deviations, were
included in the respective analysis set. The efficacy popu-
lation comprised all patients who had received ‡1 dose of
BAY 1862864 and for whom any postbaseline efficacy data
were available or who had clinical disease progression be-
fore the first postbaseline efficacy assessment (i.e., treatment
failure).
The pharmacokinetic characteristics and the biomarker
and efficacy data were summarized using descriptive
statistics.
Statistical analyses were conducted using SAS, version
9.4 (SAS Institute, Inc., Cary, NC).
The study reports only data from the dose-escalation part.
Results
Patients
Between November 20, 2015, and November 11, 2019,
28 patients were assessed for eligibility. Seven patients did
not meet the eligibility criteria, and 21 patients were en-
rolled and treated with different BAY 1862864 regimens
(Fig. 1; full analysis set/safety analysis set). The majority
(95% [20/21]) of patients had an Eastern Cooperative On-
cology Group performance status (ECOG PS) of 0–1
(Table 1). Twenty-nine percent (6/21) of patients presented
with diffuse large B cell lymphoma (DLBCL), 10% (2/21)
with DLBCL originating from transformed FL, and 48%
(10/21) with FL (Table 1). All patients (100%) had received
‡1 line of prior anticancer therapy, including rituximab
(Table 1). Seventy-six percent (16/21) of patients had re-
ceived prior chemotherapy and 29% (6/21) had received
prior chemotherapy and immunotherapy (Table 1).
Treatment
The median number of injections received for each cohort
and the number of patients who had received one to five
injections in each cohort are detailed in the Supplementary
Table S1. Dose interruption or delay was reported in 10%
(2/21) and treatment discontinuation in 5% (1/21) of patients
due to an AE (Supplementary Table S1).
Safety profile
Any-grade TEAEs occurred in 95% (20/21) of patients,
while grade ‡3 TEAEs were reported in 48% (10/21) of
patients (Table 2). The most common grade ‡3 TEAEs were
neutropenia (14% [3/21] of patients), thrombocytopenia
(14% [3/21]), and leukopenia (14% [3/21]) (Table 2).
The most common drug-related any-grade TEAE was
thrombocytopenia (48% [10/21] of patients) (Supplementary
Table S2). Grade ‡3 drug-related TEAEs were reported in
24% (5/21) of patients, with the most common being neu-
tropenia, thrombocytopenia, and leukopenia, each occurring
in 10% (2/21) of patients (Supplementary Table S2).
Eighteen patients who had completed cycle 1 assessments
were evaluable for DLTs. Three patients had not completed
cycle 1 assessments due to progressive disease (PD).
Overall, one patient experienced two DLTs, which were
grade 3 febrile neutropenia and grade 4 thrombocytopenia,
at the 4.6 MBq (10 mg antibody) radioactivity dose. No
DLTs were reported for the other tested dose levels.
All patients with QT/QTc interval measurements had a
change from the baseline in the Fredericia interval duration
of £30 ms at all time points, except for one patient at cycle 1
day 1 (1 h postadministration of BAY 1862864) in the
1.5 MBq (2 mg antibody) cohort, who had a change from the
baseline of >30–60 ms (Supplementary Table S3). Absolute
values of the QTcF interval for patients with measurements
show no QT interval prolongation (Supplementary
Table S3). No liver toxicity was reported during the treat-
ment period in any of the cohorts (data on file).
During the 12-month follow-up period, the most common
any-grade AEs were neutropenia (19% [4/21]), thrombo-
cytopenia (14% [3/21]), vomiting (10% [2/21]), and pyrexia
(10% [2/21]), and the most common grade ‡3 AEs were
thrombocytopenia (14% [3/21]) and neutropenia (10% [2/
21]) (Supplementary Table S4). Potential drug-related spinal
fractures were reported in two patients. No radiation-related
toxicities, including benign and malignant neoplasms (ex-
cept for a recurrence of a squamous cell carcinoma, resected
>5 years ago, in a 76-year-old female with FL treated with a
single 1.5 MBq [2 mg protein] dose), myelodysplastic syn-
dromes, and acute myeloid leukemia, occurred during this
period (Supplementary Table S4).
During the treatment and the follow-up period, median time
to first grade 3 or 4 thrombocytopenia for 4 patients was 40 d
(range 22–135). One patient with a prior history of HDT-
ASCT in the 1.5 MBq (2 mg antibody) cohort, who re-
ceived three injections, developed grade 3 thrombocytopenia
135 days after the first injection (Supplementary Table S5).
The median time to recovery from a grade 3 or 4 thrombo-
cytopenia nadir, which occurred in 2 patients during the
treatment and the follow-up period, both in the 4.6 MBq
(10 mg antibody) cohort, was 26 d (range 8–43) (Supple-
mentary Table S5).
Grade 3 or 4 treatment-emergent serious AEs (TESAEs)
were reported in 19% (4/21) of patients. 14% (3/21) of pa-
tients experienced at least one study drug-related TESAE
(data on file). Three (14%) patients died during the study
treatment period, but none of the deaths was deemed to be
related to BAY 1862864. Two patients in the 4.6 MBq
(10 mg antibody) cohort and one patient in the 6.1 MBq
(10 mg antibody) cohort died due to disease progression.
Pharmacokinetics
Pharmacokinetic parameters for thorium-227 in blood and
the total antibody in serum after a single dose administration












































in each treatment cohort are summarized in Table 3. Max-
imum thorium-227 blood concentrations increased pro-
portionally over the radioactivity dose range of 1.5–6.1 MBq
(Table 3). Changes in mean concentrations of thorium-227
in the blood and the total antibody in serum over time are
shown in the Supplementary Figure S1A and B. The curve
of thorium-227 concentrations in the blood over time par-
alleled that of the total antibody concentrations in serum
across treatment cohorts in cycle 1 (Supplementary
Fig. S1A, B).
Across the different radioactivity dose levels, the median
time to reach the maximum concentration (Tmax) of the total
antibody in serum was between 0.14 h and 0.55 h, and the
median time to reach the maximum activity of thorium-227
in the blood was between 0.15 h and *1 h (Table 3).
Using a high purity germanium (HPGe) detector, the whole
body measurements for thorium-227 and radium-223 were
performed in 3 patients treated with the 3.1 MBq (10 mg
antibody), the 4.6 MBq (10 mg antibody), or the 6.1 MBq
(10 mg antibody) radioactivity dose (1 patient in each dose
level). Radium-223 was observed during the elimination and
decay of thorium-227 (Supplementary Fig. S1C–E). The
thorium-227 and radium-223 measurements and those pre-
dicted based on physical decay are shown in the Supple-
mentary Figure S1C–E. The noncompartmental analysis
parameters for thorium-227 and radium-223 are detailed in
the Supplementary Tables S6 and S7, respectively.
Pharmacodynamics
Treatment with BAY 1862864 resulted in the reduction of
CD22-positive lymphocytes in the blood across all dose levels
(Supplementary Table S8). No anti-BAY 1862864 antibodies
were detected in any of the study samples analyzed from 21
patients (Supplementary Data, data on file).
Efficacy
The efficacy data are summarized in Table 4. A complete
response (CR) was achieved in 5% (1/21) of patients and a
partial response (PR) was reported in 19% (4/21) of patients
using combined Lugano-CT and Lugano-PET-CT assess-
ments according to the LUGANO criteria 2014 (Table 4).
Fourteen percent (3/21) and 52% (11/21) of patients had
stable disease (SD) and PD, respectively (Table 4). The best
overall tumor response was not evaluable in 10% (2/21) of
patients due to either discontinuation in cycle 1 or unavail-
ability of post-treatment imaging data. A total objective re-
sponse rate (ORR) (CR and PR) of 25% (5/21 patients) and
disease control rate (DCR) (CR, PR, and SD) of 38% (8/21)
were reported in the efficacy analysis data set (Table 4).
Efficacy data grouped according to indication showed an
ORR of 11% (1/9) in patients with DLBLC, including one
patient with primary mediastinal B cell lymphoma, an ORR
of 30% (3/10) in patients with FL, and a PR in a patient with
marginal zone lymphoma (Table 4).
Discussion
This first-in-human phase I study of BAY 1862864 in
patients with R/R-NHL provides proof of the concept that a
thorium-227-radiolabeled anti-CD22 antibody is safe and
may be beneficial for patients with R/R-NHL.
Table 1. Baseline Demographics and Disease
Characteristics (Safety Analysis Set)
Patients
(n = 21)















Stage at study entry
Stage I 1 (5)
Stage II 2 (10)
Stage II bulky 1 (5)
Stage III 6 (29)
Stage IV 11 (52)












Median time since initial diagnosis,
weeks (range)
124 (33–1115)
Any prior systemic anticancer therapya 21 (100)
Median (range) 3 (1–13)








Prior chemotherapy/immunotherapy 6 (29)
Prior HDT-ASCT 1 (5)
Any prior radiotherapy 8 (38)
Data are n (%) unless otherwise stated.
aChemotherapy, chemotherapy/immunotherapy, high-dose che-
motherapy/autologous transplant, monoclonal antibodies, other
immunotherapy and other anticancer therapies.
bSelected most common prior chemotherapies are shown.
DLBCL, diffuse large B cell lymphoma; ECOG PS, Eastern
Cooperative Oncology Group performance status; FL, follicular
lymphoma; FLIPI, FL international prognostic index; HCL, hairy
cell leukemia; HDT-ASCT, high-dose therapy and autologous stem
cell transplantation; IPI, international prognostic index; MZL,
marginal zone lymphoma; NA, not available; PMBCL, primary
mediastinal large B cell lymphoma.
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































BAY 1862864 at a thorium-227 radioactivity dose level
of up to 6.1 MBq (10 mg antibody) showed an acceptable
toxicity profile in patients with R/R-NHL, and no dose-
dependent or accumulative toxicity has been reported in this
limited data set. Moreover, a repeated administration of
BAY 1862864 at the 4.6 MBq (10 mg antibody) radioac-
tivity dose at *6-week intervals was feasible, with the
highest cumulative radioactivity dose reaching 13.8 MBq.
Cytopenia, fatigue, and back pain were the most frequently
reported any-grade TEAEs, while neutropenia, thrombocy-
topenia, and leukopenia were the key grade ‡3 toxicities.
Based on nonclinical dosimetry studies (data on file), bone
marrow toxicity was expected due to the estimated absorbed
dose and the sensitivity of bone marrow to radiation.
Thrombocytopenia is a concern in patients with lym-
phoma treated with radioimmunotherapy.19 Indeed, the
marrow reserve is reduced due to the numerous prior ther-
apies and treating physicians may be concerned about the
risk of prolonged and severe thrombocytopenia and the at-
tendant risk of hemorrhage.
Fourteen percent (3/21) of patients with R/R-NHL expe-
rienced grade ‡3 thrombocytopenia in this study, but the
administration of increasing doses of BAY 1862864 did not
result in a higher incidence of this complication and none of
the patients treated at the highest 6.1 MBq (10 mg antibody)
radioactivity dose level developed grade ‡3 thrombocyto-
penia. The median duration of thrombocytopenia was 8 d.
Myelosuppression is also a concern in this patient group due
to the fact that patients are often heavily pretreated before
being considered for radioimmunotherapy.
The long-term follow-up safety data showed no adverse
signal of delayed toxicity during the 12-month follow-up
period. However, a relatively short long-term follow-up
period, death due to disease progression, and termination of
the follow-up period due to enrollment of patients with PD
into other interventional studies precluded the evaluation of
the long-term safety beyond 1 year. Three patients (14%)
experienced fractures at least 6 months after the last treat-
ment. A number of factors, such as advanced age, prior
treatment with corticosteroids, chemotherapy, radiotherapy,
and old spinal fractures, may have contributed to the frac-
tures reported in this study.
Exposure to BAY 1862864 increased in a dose-proportional
manner after administration of single radioactivity doses over
a range of 1.5–6.1 MBq. Parallel time-concentration curves
of thorium-227 and the total antibody across different
treatment cohorts demonstrate the stability of BAY 1862864
in the blood.
The data collected using an HPGe radiation detector
showed the median whole body half-life and the mean res-
idence time (15.8 and 20.6 d, respectively) of thorium-227
to be in the same range as the physical half-life (18.7 d),
which suggests that thorium-227 is eliminated from the
body mainly through physical decay. In contrast, a com-
parison of the whole body activity of radium-223 measured
with an HPGe detector and the predicted natural decay
curves following administration of 3.1, 4.6, or 6.1 MBq (all
at 10 mg antibody) dose, together with patient imaging data
generated with the gamma camera,18 suggest that radium-
223 predominantly undergoes biological elimination, most
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The efficacy data observed in this study indicate the first
signs of potential clinical efficacy, with one CR being re-
ported at the 3.1 MBq and four PRs at the 1.5, 3.1, and
4.6 MBq radioactivity dose levels. Importantly, patients with
FL showed higher CR, PR, ORR, and DCR than patients
with DLBCL, who had very aggressive disease and had
either progressed or died following the treatment with a
single BAY 1862864 dose in cycle 1.
Previous studies have demonstrated the efficacy of
radioimmunotherapy in patients with NHL. Notably, pa-
tients with NHL without prior ASCT treated with the b-
emitter yttrium-90-labeled epratuzumab tetraxetan achieved
an ORR of 71%, including patients with bulky disease and
poor prognosis, while patients with FL reported an ORR of
100%.13 Radioimmunotherapy with yttrium-90-labeled
ibritumomab tiuxetan in patients with follicular R/R-NHL
showed an overall response rate of 80% versus 56% in the
rituximab-treated control group,22 and it was 74% in pa-
tients with rituximab-refractory follicular NHL.2
In this study, the small sample size, disease heterogeneity
at baseline, and the early termination of the trial due to
reasons other than safety and efficacy of BAY 1862864
precluded the proper evaluation of a response rate.
Conclusions
The safety data reported in this study show that BAY
1862864 is safe and tolerated in patients with R/R-NHL.
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